{"entity":{"id":"youn-kim","kind":"person","name":"Youn H. Kim","aka":[],"tldr":"Stanford dermatologist who led MAVORIC, the trial that established mogamulizumab for mycosis fungoides and Sézary syndrome after earlier treatment.","summary":"Youn Kim directs the cutaneous lymphoma programme at Stanford. She was first author of the 2018 Lancet Oncology report of MAVORIC, the phase 3 trial in which the anti-CCR4 antibody mogamulizumab improved progression-free survival compared with vorinostat in previously treated mycosis fungoides and Sézary syndrome, the basis for its approval. She has led many trials of new agents in cutaneous T-cell lymphoma and helped define its staging and response criteria.","asOf":"2026-09-18","links":[],"tags":["lymphoma","dermatology","trialist"],"related":[],"cancers":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":["mavoric"],"people":[],"bottlenecks":[],"keyPapers":["paper-mavoric-mogamulizumab-lancet-oncol-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Dermatologist and Director of the Multidisciplinary Cutaneous Lymphoma Program, Stanford","institutionId":"stanford","specialisms":["Cutaneous T-cell lymphoma","Mycosis fungoides and Sézary syndrome","Novel therapies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%5BAuthor%5D"}],"papers":[],"orcid":"0000-0003-2686-5873"},"route":"/people/youn-kim/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"institution":[{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/"}],"trial":[{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/"}],"paper":[{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/"}]}}